- IMV Inc IMV announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL).
- Related: IMV’s MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity
- 8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy;
- Of these six evaluable patients, three showed confirmed complete responses, one was assessed with a stable disease as the best response, and two were assessed with progressive disease as the best response.
- Two patients with a poor level of baseline functionality (ECOG ≥ 2) failed to stay on the study through to the first scan and, therefore, could not be evaluated.
- Price Action: IMV shares are down 15.15% at $1.68 on the last check Monday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
